METTL3/ METTL14 upregulation enhanced the resistance of oral squamous cell carcinoma (OSCC) to cisplatin by inhibiting the interleukin -17 (IL-17) signaling [136]. This evidence concerns the gene IL17A and oral cavity squamous cell carcinoma.